Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Alison Yan Zhang"'
Autor:
Stephen Begbie, Wendy R. Parulekar, Scott North, Francis Parnis, Alvin Tan, David Pook, John McCaffrey, Xanthi Coskinas, Thean Hsiang Tan, M. Neil Reaume, Scott Williams, Francisco E. Vera-Badillo, Alastair Thomson, Emily Tu, Shahneen Sandhu, Alison Yan Zhang, Andrew J. Martin, Anthony M. Joshua, Lisa G. Horvath, Nicola Jane Lawrence, Margaret McJannett, Wendy Hague, Martin R. Stockler, Ian D. Davis, Christopher Sweeney, Robert Zielinski, Ray McDermott, Mark Frydenberg, Simon Chowdhury, Gavin Marx, Kim N. Chi, Sonia Yip
Publikováno v:
European Urology. 80:275-279
Men who initially present with localized prostate cancer and later develop metachronous metastases have a better prognosis than men with de novo metastatic disease and often have a low burden of disease on conventional imaging. Some have disease amen
Autor:
Ben Tran, Thomas G. Meikle, Ian D. Davis, Edmond M. Kwan, Arun Azad, Patricia Bastick, Gavin Marx, Jordan F Hastings, Nicole Yeung, Natalie A. Mellett, Peter J. Meikle, Anthony M. Joshua, Martin R. Stockler, Karen Briscoe, David R. Croucher, Alison Yan Zhang, Kevin Huynh, Hui-Ming Lin, Lisa G. Horvath, Megan L Crumbaker, Kate L. Mahon
Publikováno v:
Cancers, Vol 13, Iss 4964, p 4964 (2021)
Cancers
Volume 13
Issue 19
Cancers
Volume 13
Issue 19
Circulating lipids or cytokines are associated with prognosis in metastatic castration-resistant prostate cancer (mCRPC). This study aimed to understand the interactions between lipid metabolism and immune response in mCRPC by investigating the relat
Autor:
Ian D. Davis, Amir Iravani, Margaret McJannett, Louise Emmett, Scott Williams, Martin R. Stockler, Arun Azad, Roslyn J. Francis, Andrew J. Martin, John Violet, Michael S Hofman, Nicola Jane Lawrence, Alison Yan Zhang
Publikováno v:
BJU International. 124:5-13
Objective To assess the activity and safety of cabazitaxel chemotherapy vs that of treatment with 177 Lu-PSMA-617, a novel radiolabelled small molecule that binds with high affinity to prostate-specific membrane antigen (PSMA), in men with metastatic
Autor:
Zeyad D. Nassar, Meghna S. Kakani, Andrew J. Hoy, Hui-Ming Lin, Jeff Holst, Lisa S. Lee, Robert F. Shearer, Lisa G. Horvath, Darren N. Saunders, Elham Hosseini-Beheshti, Margaret M. Centenera, Lisa M. Butler, Seher Balaban, Shilpa R. Nagarajan, Mark Schreuder, Nikki L. Raftopulos, Frank Liu-Fu, Atqiya Aishah, Bianca Varney, Alison Yan Zhang, Rae-Anne Hardie
Publikováno v:
Molecular Cancer Research. 17:949-962
Prostate cancer cells exhibit altered cellular metabolism but, notably, not the hallmarks of Warburg metabolism. Prostate cancer cells exhibit increased de novo synthesis of fatty acids (FA); however, little is known about how extracellular FAs, such
Autor:
Wayne D. Tilley, Maret Böhm, James G. Kench, K. Rasiah, Susan Henshall, Karen E. Knudsen, Warick Delprado, Phillip D. Stricker, Stephen B. Fox, Karen Chiam, Simone Birch, Lisa M. Butler, Carmela Ricciardelli, Ygal Haupt, Clay de Comstock, Kate L. Mahon, Alison Yan Zhang, Lisa G. Horvath, Tina Bianco-Miotto, Judith Grogan
Publikováno v:
International Journal of Cancer. 144:1151-1159
A plethora of individual candidate biomarkers for predicting biochemical relapse in localized prostate cancer (PCa) have been proposed. Combined biomarkers may improve prognostication, and ensuring validation against more clinically relevant endpoint
Autor:
Arun Azad, Shalini Subramaniam, Andrew J. Martin, Sonia Yip, Ian D. Davis, Alison Yan Zhang, Ailsa Langford, Louise Emmett, Anthony M. Joshua, Jenna Mitchell, Martin R. Stockler, Craig Gedye, Roslyn J. Francis, Margaret McJannett, Megan Crumbaker, Nisha Rana, Michael S Hofman, Shahneen Sandhu
Publikováno v:
BJU internationalReferences. 128(5)
Objectives To determine the activity and safety of lutetium-177 (177 Lu)-prostate-specific membrane antigen (PSMA)-617 in men with metastatic castration-resistant prostate cancer (mCRPC) commencing enzalutamide, who are at high risk of early progress
Autor:
Emilia Ip, David Smith, Blossom Mak, Tahlia Scheinberg, Anthony Linton, Madeleine Cornelia Strach, Annabel Goodwin, Ben Tran, Alison Yan Zhang, Martin R. Stockler, Alison Luk Young, Lisa G. Horvath, Kate L. Mahon
Publikováno v:
JCO oncology practice. 17(2)
PURPOSE: To identify the approximately 12% with inherited cancer predisposition, all men with metastatic prostate cancer (mPC) should be offered germline genetic testing. This guides treatment choices and impacts cancer prevention in the family. Limi
Autor:
Blossom Mak, Hui-Ming Lin, Kate Lynette Mahon, Anthony M. Joshua, Martin R. Stockler, Howard Gurney, Francis Parnis, Alison Yan Zhang, Tahlia Scheinberg, Gary Wittert, Lisa Butler, Andrew Hoy, Peter Meikle, Lisa Horvath
Publikováno v:
Journal of Clinical Oncology. 40:154-154
154 Background: Elevated circulating sphingolipids are associated with poorer outcomes across the natural history of prostate cancer (PC), including metastatic relapse in localised PC, earlier androgen deprivation failure in metastatic hormone-sensit
Autor:
Gavin Marx, Heidi Fettke, Megan Crumbaker, Kate L. Mahon, Anthony M. Joshua, Kevin Huynh, Ian D. Davis, Pan Du, Arun Azad, Martin R. Stockler, Thomas G. Meikle, Nicole K. Yeung, Phillip D. Stricker, Tahlia Scheinberg, Paul D. Bonnitcha, Karen Briscoe, Shidong Jia, Hui-Ming Lin, Lisa G. Horvath, Ben Tran, Alison Yan Zhang, Natalie A. Mellett, Michael Fitzpatrick, Peter J. Meikle, Edmond M. Kwan, Blossom Mak, Lisa M. Butler, David R. Sullivan, Jianjun Yu
Publikováno v:
EBioMedicine, Vol 72, Iss, Pp 103625-(2021)
EBioMedicine
EBioMedicine
Background Intrinsic resistance to androgen receptor signalling inhibitors (ARSI) occurs in 20–30% of men with metastatic castration-resistant prostate cancer (mCRPC). Ceramide metabolism may have a role in ARSI resistance. Our study's aim is to in
Autor:
Alison Yan Zhang, Judith Grogan, Phillip D. Stricker, Paul Sved, James G. Kench, Susan Henshall, Kate L. Mahon, John Boulas, A. Vasilaris, David Eisinger, Lisa G. Horvath, K. Rasiah
Publikováno v:
Annals of Oncology. 28:1903-1909
Background Prostate cancers (PCs) with similar characteristics at the time of diagnosis can have very different disease outcomes. Conventional biomarkers of PC still lack precision in identifying individuals at high risk of PC recurrence. While many